Compounds > 13,14-dihydro-15-ketoprostaglandin e1
Page last updated: 2024-12-08
13,14-dihydro-15-ketoprostaglandin e1
Description
13,14-dihydro-15-ketoprostaglandin E1 (13,14-dihydro-15-keto-PGE1) is a **metabolite** of **prostaglandin E1 (PGE1)**. It's formed by the reduction of the 15-keto group in PGE1.
Here's why it's important for research:
* **Marker for PGE1 metabolism:** 13,14-dihydro-15-keto-PGE1 is a stable metabolite of PGE1 and is often used as a marker to assess PGE1 metabolism in various biological systems. This is especially useful for analyzing samples where PGE1 itself might be unstable or difficult to measure directly.
* **Potentially different biological activity:** While 13,14-dihydro-15-keto-PGE1 is derived from PGE1, it may exhibit different biological activities due to the structural changes. Research is ongoing to understand its specific effects on various biological systems.
* **Potential therapeutic targets:** The potential biological activity of 13,14-dihydro-15-keto-PGE1 and its relationship to PGE1 metabolism could make it a potential therapeutic target for various conditions, including inflammation, pain, and cardiovascular disease.
**Specifically, research on 13,14-dihydro-15-keto-PGE1 focuses on areas like:**
* **Renal function:** Studies have investigated its role in regulating renal blood flow and sodium excretion.
* **Inflammatory responses:** Research explores its potential involvement in inflammatory processes and its interaction with other inflammatory mediators.
* **Cancer:** Studies have examined its potential role in cancer development and progression.
* **Neurological disorders:** Research investigates its potential impact on neuronal function and its role in conditions like stroke and Alzheimer's disease.
Overall, 13,14-dihydro-15-keto-PGE1 is a fascinating molecule with potential implications for various biological processes and diseases. Further research is needed to fully elucidate its biological activity and therapeutic potential.
13,14-dihydro-15-ketoprostaglandin E1: pulmonary metabolite of PGE1 in dogs; RN given refers to (11alpha)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
13,14-dihydro-15-oxoprostaglandin E1 : A prostaglandin E obtained by formal oxidation of the 15-hydroxy group and hydrogenation of the 13,14-double bond of prostaglandin E1. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 165284 |
| CHEBI ID | 134499 |
| SCHEMBL ID | 15218007 |
| MeSH ID | M0111802 |
Synonyms (39)
| Synonym |
|---|
| 5094-14-4 |
| 13,14-dihydro-15-keto-pge1 |
| 13,14-dihydro-15-keto-prostaglandin e1 |
| 9,15-dioxo-11r-hydroxy-prostanoic acid |
| LMFA03010145 , |
| (11alpha)-11-hydroxy-9,15-dioxoprostan-1-oic acid |
| 15-keto-13,14-dihydro-pge1 |
| u 21002 |
| 13,14-dihydro-15-oxo-pge1 |
| 13,14-dihydro-15-ketoprostaglandin e1 |
| CHEBI:134499 |
| 13,14-dihydro-15-oxoprostaglandin e1 |
| 7-[(1r,2r,3r)-3-hydroxy-5-oxo-2-(3-oxooctyl)cyclopentyl]heptanoic acid |
| 15-keto-pge(0) |
| 15-keto-pge0 |
| m3i99mym0v , |
| unii-m3i99mym0v |
| prostan-1-oic acid, 11-hydroxy-9,15-dioxo-, (11alpha)- |
| 13,14-dihydro-15-keto prostaglandin e1 |
| SCHEMBL15218007 |
| prprostan-1-oic acid, 11-hydroxy-9,15-dioxo-, (11.alpha.)- |
| 11.alpha.-hydroxy-9,15-dioxoprostanoic acid |
| 11.alpha.-hydroxy-9,15-diketoprostanoic acid |
| 15-oxo-pge0 |
| dihydro-15-ketoprostaglandin e1 |
| 15-keto-prostaglandin e0 |
| u-21002 |
| 15-oxodihydroprostaglandin e1 |
| HMS3648D03 |
| 11a-hydroxy-9,15-diketoprostanoic acid |
| 9,15-dioxo-11alpha-hydroxy-prostan-1-oic acid |
| sr-01000946406 |
| SR-01000946406-1 |
| 15-keto prostaglandin e0 |
| Q27283444 |
| 13,14-dihydro-15-keto pge1 |
| DTXSID201311666 |
| PD021177 |
| AKOS040755074 |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|
| " Pharmacokinetic parameters were calculated for four experimental designs including single-dose bolus injections (30, 10, and 3 micrograms PGE1/kg): single-dose, 4-h continuous infusions (20 and 320 ng/kg/min): multiple-dose continuous infusions (5, 20, 80, and 320 ng/kg/min); and single-dose, 30-day chronic infusions (100 ng/kg/min)." | ( In vivo disposition of prostaglandin E1 via pharmacokinetic characterization of its pulmonary metabolite.
Bothwell, W; Daniels, EG; Fitzpatrick, FA; Verburg, M, ) | 0.13 |
Roles (1)
| Role | Description |
|---|
| human xenobiotic metabolite | Any human metabolite produced by metabolism of a xenobiotic compound in humans. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (1)
| Class | Description |
|---|
| prostaglandins E | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.25
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.25 (24.57) | | Research Supply Index | 2.20 (2.92) | | Research Growth Index | 4.45 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 1 (14.29%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (85.71%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |